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Background: Little is known about the significance of blood transfusion in patients with peripheral arterial disease. We
queried the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database to
examine the effect of intraoperative blood transfusion on the morbidity and mortality in patients who underwent lower
extremity revascularization.
Methods: We analyzed data from the participant use data file containing vascular surgical cases submitted to the ACS
NSQIP in 2005, 2006, and 2007 by 173 hospitals. Current procedural terminology codes were used to select lower
extremity procedures that were grouped into venous graft, prosthetic graft, or thromboendarterectomy. Thirty-day
outcomes analyzed were (1) mortality, (2) composite morbidity, (3) graft/prosthesis failure, (4) return to the operating
room within 30 days, (5) wound occurrences, (6) sepsis or septic shock, (7) pulmonary occurrences, and (8) renal
insufficiency or failure. Intraoperative transfusion of packed red blood cells was categorized as none, 1 to 2 units, and 3
or more units. Outcome rates were compared between the transfused and nontransfused groups using the 2 test and
multivariable regression adjusting for transfusion propensity, comorbid and procedural risk.
Results: A total of 8799 patients underwent lower extremity revascularization between 2005 and 2007. Mean age was
66.8 12.0 years and 5569 (63.3%) were male. Transfusion rates ranged from 14.5% in thromboendarterectomy patients
to 27.1% in prosthetic bypass patients (P< .05). After adjustment for transfusion propensity and patient and procedural
risks, transfusion of 1 or 2 units remained significantly predictive of mortality, composite morbidity, sepsis/shock,
pulmonary occurrences, and return to the operating room. The adjusted odds ratios for 30-day mortality ranged from
1.92 (95% confidence interval [CI] 1.36-2.70) for 1 to 2 units to 2.48 (95% CI 1.55-3.98) for 3 or more units.
Conclusion: In a large number of patients undergoing lower extremity revascularization, we have found that there is a
higher risk of postoperative mortality, pulmonary, and infectious complications after receiving intraoperative blood
transfusion. Additional studies are necessary to better define transfusion triggers that balance the risk/benefit ratio for
blood transfusion. (J Vasc Surg 2010;51:616-21.)The population of patients with peripheral arterial dis-
ease (PAD) is steadily advancing in age, and older patients
with multiple comorbid conditions undergo lower extrem-
ity revascularization. Red blood cell (RBC) transfusion is a
common event in the perioperative course of these patients.
This practice is not without risk. Worse outcomes in trans-
fused patients have been observed in various settings such
as critically ill patients, elderly patients, cardiac surgery/
trauma/orthopedic surgical patients, and patients with
acute coronary syndrome. In these studies, patients receiv-
ing allogeneic transfusions have had higher mortality rates,
higher risk of intensive care unit (ICU) admission, longer
hospital and ICU stays, higher postoperative infection
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616rates, higher risk of developing adult respiratory distress
syndrome (ARDS), longer time to ambulation, higher in-
cidence of atrial fibrillation, and higher risk of ischemic
outcomes compared with nontransfused cohorts.1-6 Little
is known about the significance of RBC transfusion in
patients with PAD.We queried the National Surgical Qual-
ity Improvement Program (NSQIP) database to examine
the effect of intraoperative blood transfusion on the mor-
bidity and mortality in patients who underwent lower ex-
tremity revascularization.
METHODS
Study population. The American College of Sur-
geons (ACS) National Surgical Quality Improvement Pro-
gram (NSQIP) is a reporting system designed to provide
reliable, risk-adjusted surgical outcomes data to surgical
services and administrators at medical centers throughout
the private sector so that surgical quality can be assessed and
improved on a national level.We analyzed the data from the
participant use data file containing vascular surgical cases
submitted to the ACS NSQIP in 2005, 2006, and 2007 by
173 hospitals throughout the United States.
Data collection. The ACS NSQIP collects data on
135 variables, including preoperative risk factors, intraop-
erative variables, and 30-day postoperative morbidity and
 .0
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dures in both the inpatient and outpatient setting. Data are
prospectively collected in a standardized fashion according
to strict definitions by dedicated surgical clinical nurse
reviewers. Patients are followed throughout their hospital
course and after discharge from the hospital up to 30 days
postoperatively. Nurse reviewers collect data from comput-
erized and paper patient medical records, doctor’s office
records, and telephone interviews with patients. The accu-
racy and reproducibility of the data have been previously
demonstrated.7-9 Primary procedure current procedural ter-
minology (CPT-4) codes were used to select lower extremity
procedures, whichwere grouped into venous graft (CPT code
35533, 35541, 35546, 35556, 35558, 35565, 35566,
35571, 35583, 35585, or 35587), prosthetic graft (CPT
code 35646, 35647, 35654, 35656, 35661, 35665,
35666, or 35671) or thromboendarterectomy (CPT code
35371, 35372, or 35381). Thirty-day outcomes analyzed
were (1) mortality, (2) composite morbidity (one or more
of 21 adverse events uniformly defined by the ACSNSQIP,
including all of the following subgroups), (3) graft/pros-
thesis failure (defined as “mechanical failure of an extra-
cardiac graft or prosthesis . . . requiring return to the op-
erating room, interventional radiology, or a balloon
angioplasty.” ), (4) return to the operating room for any
reason within 30 days, (5) wound occurrences (superficial,
deep or organ/space surgical site infection and/or wound
dehiscence), (6) sepsis or septic shock, (7) pulmonary
occurrences (ventilation greater than 48 hours, pneumonia
and/or unplanned intubation), and (8) renal insufficiency
or failure (defined as “the reduced capacity of the kidney to
perform its function as evidenced by a rise in creatinine of
2 mg/dL from preoperative value, but with no require-
ment for dialysis”).
Intraoperative transfusion of packed RBCs was catego-
rized as none, 1 to 2 units, and 3 or more units. Preopera-
tive hematocrit is measured according to the value closest
to the entry to the operating room. Outcome rates were
compared between the transfused and nontransfused
groups using the 2 test. Significant P values for the multi-
ple comparisons were adjusted to .005.
The risk (propensity) of intraoperative transfusion in
this patient population was calculated using logistic regres-
sion of more than 55 ACS NSQIP patient risk factors in a
forward stepwise fashion (P for entry .05, for exit .10)
followed by the addition of procedure group and complex-
ity (work relative value units [RVUs]). Patients were ranked
Table I. Intraoperative transfusion rates and 30-day outco
Lower extremity revascularization procedure n, %
Bypass w/prosthetic 3696, 42
Bypass w/vein 4076, 46
Thromboendarterectomy 1027, 12
Total 8799, 100
Transfusion and morbidity rates varied significantly by procedure type, 2 Pinto five equal-sized groups (quintiles) based on their trans-fusion propensity. Within each quintile, the numbers of
transfused and nontransfused patients were counted, and
themortality rates were compared using 2 tests (P .01 to
correct for multiple comparisons). This was performed as a
high-level omnibus test to aid in visualization prior to the
more powerful multivariable analysis.
The odds ratios (ORs) by transfusion category were
calculated for each of the outcomes using logistic regres-
sion (P  .005 was considered significant to correct for
multiple comparisons). Adjusting variables included trans-
fusion propensity, independent patient risk factors included
in a forward stepwise fashion (P for entry .05, for exit
.10), wound class, operative duration, procedure type,
and complexity. Transfusion category was added at the end
to the model. (Appendix Table AI, online only).
RESULTS
The ACS NSQIP database contained 8799 patients
who underwent lower extremity revascularization between
2005 and 2007. Their mean age was 66.8 12.0 years and
5569 (63.3%) were male. Transfusion rates varied across
procedure group, ranging from 14.5% in thromboendar-
terectomy patients to 27.1% in prosthetic bypass patients
(2 P  .05, Table I).
The amount of RBC units given by preoperative he-
Fig 1. Mean number of units of packed red blood cells given
intraoperatively by preoperative hematocrit level. Lower extremity
revascularization patients, n  8799.
by type of lower extremity revascularization procedure
Transfused % Mortality % Morbidity %
27.1 3.1 25.4
20.1 2.5 27.1
14.5 3.4 19.7
22.4 2.9 25.5
5.mesmatocrit (Hct) appears in Fig 1. The transfusion propensity
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ative risk factors (Appendix Table AI, online only). The 10
most significant predictors of transfusion in lower extremity
revascularization patients, by order of entry into the model
were (1) preoperative Hct, (2) procedure group and (3)
complexity (work RVUs), (4) American Society of Anes-
thesiologists’ physical status classification [ASA class], (5)
general anesthesia versus other, (6) prior coronary inter-
vention, (7) emergent status, (8) age, (9) alkaline phospha-
tase greater than 125 U/L, and (10) serum albumin (g/
dL, inverse relationship).
Transfusion rates ranged from 4.4% in the lowest
propensity quintile to 52.9% in the high propensity
quintile. The Mantel-Haenszel common odds ratio esti-
mate across propensity quintiles was 2.13 (95% confi-
dence interval [CI], 1.61-2.81; P  .001). The Breslow-
Day test did not support rejecting homogeneity (P 
.288). The mortality rate was significantly higher in
transfused patients versus nontransfused for the highest
and low–middle quintiles (2 P  .01, Fig 2). Mortality
was threefold overall in transfused patients (6.2% in
transfused patients vs 1.9% in nontransfused). All unad-
justed outcomes examined were significantly higher in
transfused patients (2 P  .001, Table II).
Each of the outcome multivariable regression models
was highly significant in predicting each outcome (2 P 
.001) and discrimination (c-indices) ranged from 0.66
(graft failure) to 0.85 (mortality). The mortality and com-
posite morbidity models are shown in the Appendix Tables
AII and AIII, online only. After adjustment for transfusion
propensity and patient and procedural risks, transfusion of
1 or 2 units remained significantly (P .005) predictive of
mortality, composite morbidity, sepsis/shock, pulmonary
occurrences, and return to the operating room. Risks for
these outcomes increased with level of transfusion (Table
II), although the significance of the increase was not deter-
mined. The adjusted odds ratios for 30-day mortality
Fig 2. Mortality in transfused vs nontransfused patients within
groups matched by their preoperative risk (propensity) of intraop-
erative transfusion. *2 P  .01.
Propensity is the estimated risk based on regression of preop-
erative hematocrit, procedure type and complexity, ASA class,
emergent status, age, and 18 other risk factors vs whether or not
the patient received a transfusion intraoperatively. The propensity
regression model is in the Appendix.ranged from 1.92 (95% CI, 1.36-2.70) for 1 to 2 units to2.48 (95% CI, 1.55-3.98) for 3 or more units (Wald P 
.001).
DISCUSSION
Blood product transfusion is a common event during
peripheral vascular operations with the goal of replacing
volume and increasing blood oxygen carrying capacity.10
Dramatic improvements in reduction of transmission of
infectious agents11,12 have led to new and increased focus
on other serious hazards of transfusion such as multiple
system organ failure associated with cytokine release, bac-
terial contamination, sepsis, metabolic disturbances, circu-
latory overload, hemolytic reactions, and risk of old blood.
After removal from the body and with the added effect
of storage, RBCs undergo changes (many irreversible) that
adversely affect their viability and function. These adverse
changes include oxidation and rearrangement of lipids, loss
of proteins, and depletion of ATP and 2, 3-diphosphoglycerate.
In storage, RBCs continuously lose their membrane
through shedding vesicles and become rigid. Moreover,
during storage, bioactive by-products and ions (hemoglo-
bin, lipids, and potassium)—some with proinflammatory
effects—are released from RBCs and accumulate in blood
units whereby they can cause adverse reactions in a recipi-
ent. These changes are collectively called “storage lesion.”
Transfusion of blood that is stored for prolonged periods
(but still within the currently accepted maximum allowed
storage time of 42 days) has been linked to increased risk of
complications and reduced survival in patients undergoing
cardiac surgery and in other patient populations.13-17
Studies in cardiac surgery patients associated transfu-
sion with increased mortality, higher incidence of postop-
erative infection, prolonged respiratory support, higher risk
of postoperative infection, and higher risk of renal fail-
ure.4,8 Similarly, in critical care patients, transfusion has
been associated with increased overall and ICU 14-day
mortality rate, higher 28-day mortality rate, longer length
of stay, higher risk of developing ARDS, and higher inci-
dence of bloodstream infections.18-22
We focused on the risks of blood transfusion in
patients following peripheral vascular operations and
using the NSQIP database examined 30-daymorbidity and
mortality. Our data suggest that after risk adjustment,
patients receiving intraoperative transfusion are at higher
risk of developing morbidity and mortality.
Transfusion-associated lung injury (TRALI) is a well
recognized complication and is considered to be the second
leading cause of mortality from transfusion.23,24 In our
population, therewas almost a threefold overall increase in the
incidence of pulmonary complications in transfused patients,
transfusion of 3 or more units carried an even higher risk as
compared with 1 to 2 units. The pathophysiologic mecha-
nisms of TRALI are incompletely understood and have been
described as antibody-mediated and nonantibody-mediated.
In both cases, activation of neutrophils plays a causal role, and
these activated cells are thought to locally mediate pulmonary
injury.25,26
te infe
entilat
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 3 O’Keeffe et al 619The threshold at which a patient receives a blood
transfusion is arbitrary, depending on the culture of prac-
tice at various different institutions. The optimal range of
hematocrit values that balances the associated complica-
tions of blood transfusion with complications related to
anemia is unknown. Habib et al27 reported that the lowest
hematocrit value on cardiopulmonary bypass (22%) was
associated with increased morbidity and was predictive of
worse 0- to 6-year survival. Although Wu et al28 described
a benefit for RBC transfusion in patients who were elderly
and had low admission hematocrit values (30%), they also
reported that for those patients with hematocrit values of
36% and who received transfusions had a higher risk of
death within 30 days than patients with a similar hematocrit
who did not receive blood. In a randomized, controlled
trial of 838 critically ill patients, Hebert29 reported similar
overall 30-daymortality for a restrictive transfusion strategy
(hemoglobin levels maintained between 7 and 9 g/dL) vs a
more liberal strategy (hemoglobin levels maintained be-
tween 10 and 12 g/dL). Although mortality was similar in
the two groups, it was significantly lower with the restric-
tive strategy among patients whowere less acutely ill. Because
we found that transfusionwas not limited to patients with low
Hct in our population, we carried out a propensity risk assess-
ment based on preoperative Hct, procedure type and com-
plexity, ASA class, emergent status, age, and 18 other risk
factors vs whether or not the patient received a transfusion
intraoperatively. The propensity regression showed that mor-
tality is significantly higher in transfused vs nontransfused
patients within groups matched by their preoperative risk
(propensity) of intraoperative transfusion, even for low- and
medium-propensity patients.
The immunologic effects of blood transfusion may be
responsible for the observed increase in risk of infection in
blood-transfused patients. Blood transfusions have been
shown to be independent risk factor for infection.30,31
Table II. Thirty-day outcomes for lower extremity revascu
Outcome
Not
transfused Transfused 2
6827, 77.6 1971, 22.4
Mortality, % 1.9 6.2
Morbidity, % 21.7 38.8
30-d graft failure, % 4.8 7.8
Return to OR, % 15.4 26.8
Wound occurrence,b % 10.5 14.4
Sepsis/shock, % 5.0 12.9
Pulmonary occurrence,c % 3.5 14.5
Renal insufficiency/failure, % 1.0 3.0
CI, Confidence interval; OR, operating room.
Unadjusted rates and odds ratios adjusted for transfusion propensity, all
complexity.
aEach outcome regression model included transfusion propensity, all indepe
regression, procedure group and complexity, wound class, and operative du
overall morbidity models are shown in the Appendix. Others are not shown
bWound occurrences included superficial, deep and organ/space surgical si
cPulmonary occurrences included pneumonia, unplanned intubation, and vTransfusion-related immunomodulation (TRIM) includesboth alloimmunization of the host and immune activation
as well as tolerance manifested as cancer recurrence, im-
proved allograft survival, and higher rates of postoperative
infections.32,33 Leukoreduction may decrease postopera-
tive infections,34 and today, most RBC transfusions in the
US are leukoreduced; however, the cost-effectiveness of
leukoreduction has yet to be proven, especially in low-risk
populations.35
A limitation of our study is that the transfusion propen-
sity was calculated based on preoperative hematocrit values
possibly not accurately reflecting acute intraoperative blood
loss. There are other factors not captured by the NSQIP
database that can affect the outcome of the revasculariza-
tion procedure as well as the need for intraoperative blood
transfusion, including the skill and experience of the sur-
geon and technical difficulty of the procedure. We took
into account in our propensity and risk models adjustment
for operative duration, wound class, work RVUs, emer-
gency status, and use of preoperative transfusion, which
capture some of the variation due to skill and difficulty.
To conclude, our study in a large number of patients
undergoing lower extremity revascularization indicates that
allogeneic intraoperative transfusion is associated with
higher postoperative morbidity and mortality. This finding
is true after adjusting for propensity for transfusion, thus,
the reason that transfused patients do poorly is not because
they have a lower preoperative hematocrit. When do the
risks of anemia outweigh the hazards of transfusion? In the
absence of acute bleeding, hemoglobin levels consistent
with the TRICC trial (7.0-9.0 g/dL) are well tolerated.29
There is little evidence that RBC transfusion in the non-
bleeding patient with a hemoglobin concentration greater
than 7.0 g/dL leads to improved outcome. Clinicians
should use hemodynamic and physiologic parameters such
as blood pressure, heart rate, and urine output in conjunc-
tion with hemoglobin levels to decide whether a patient
ation patients transfused intraoperatively vs not
lue
Propensity and risk-adjusteda
transfusion odds ratio (95% CI)
Wald P value
across categories
1-2 u. 3 u.
1 1.92 (1.36-2.70) 2.48 (1.55-3.98) .001
1 1.37 (1.19-1.58) 1.81 (1.46-2.24) .001
1 1.28 (1.00-1.64) 1.09 (0.74-1.62) .151
1 1.29 (1.10-1.51) 1.35 (1.06-1.72) .002
1 1.20 (0.99-1.45) 1.33 (1.00-1.77) .059
1 1.41 (1.12-1.77) 2.11 (1.56-2.86) .001
1 2.23 (1.75-2.85) 3.68 (2.68-5.06) .001
1 1.17 (0.71-1.94) 2.44 (1.36-4.40) .009
ant ACS NSQIP preoperative patient risk factors, procedure group, and
y significant ACS NSQIP adjusting risk factors included in forward stepwise
with level of intraoperative transfusion added at the end. The mortality and
ction and wound dehiscence.
ion greater than 48 hours.lariz
P va
.00
.00
.00
.00
.00
.00
.00
.00
signific
ndentl
ration
.needs to be transfused.
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to determine the risk/benefit of RBC transfusion in various
disease states, the optimal transfusion trigger, and the
effects of blood storage time and leukodepletion on clinical
outcomes.
The American College of Surgeons National Surgical
Quality Improvement Program and the hospitals partici-
pating in the ACS NSQIP are the source of the data used
herein; they have not verified and are not responsible for
the statistical validity of the data analysis or the conclusions
derived by the authors.
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Entry order Variables in the equation
1 Preop hematocrit vs 48%
24%
28%
32%
36%
40%
44%
48%
2 Procedure vs thromboendarterectomy
Bypass w/prosthetic
Bypass w/vein
3 Work RVUs
4 ASA class vs 1
ASA 2
ASA 3
ASA 4
ASA 5
5 General anesthetic vs other
6 Prior coronary intervention
7 Emergency status
8 Age
9 Alkaline phosphatase 125
10 Serum albumin
11 Known bleeding disorder
12 Functional status vs independent
Partially dependent
Fully dependent
13 Platelets 150
14 Male vs female
15 PT 13.2
16 Prior periph. vasc. procedure
17 Hx CHF, AMI or angina
18 Diabetes vs not treated
Orally treated
Insulin treated
19 Platelets 400
20 Preop transfusion 4 u. RBCs
21 EtOH 2 drinks/day
22 Preop renal failure
23 BUN 40
Constant
AMI, Acute myocardial infarction; ASA, American Society of Anesthesiologmodel, c-index  0.79
Odds ratio
95% CI OR
Sig.Lower Upper
.000
23.026 11.439 46.353 .000
18.633 10.941 31.731 .000
8.423 5.110 13.884 .000
4.165 2.545 6.816 .000
2.454 1.506 3.998 .000
1.854 1.133 3.033 .014
1.362 .809 2.293 .245
.000
.889 .703 1.125 .329
.349 .269 .453 .000
1.148 1.133 1.164 .000
.000
.276 .115 .664 .004
.457 .198 1.055 .066
.609 .262 1.418 .250
.594 .170 2.072 .414
2.267 1.810 2.838 .000
1.448 1.283 1.634 .000
1.626 1.329 1.990 .000
1.010 1.005 1.015 .000
1.523 1.237 1.875 .000
1.390 1.236 1.563 .000
1.228 1.078 1.399 .002
.004
1.292 1.109 1.505 .001
1.191 .840 1.689 .326
1.412 1.153 1.727 .001
.806 .716 .907 .000
1.183 1.052 1.331 .005
1.178 1.049 1.323 .006
1.303 1.062 1.600 .011
.019
.833 .713 .972 .021
.844 .725 .984 .030
1.275 1.049 1.548 .015
2.657 1.122 6.288 .026
1.276 1.016 1.603 .036
.566 .343 .934 .026
1.261 1.018 1.561 .034
.000 .000
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Step Variable Sig. Odds ratio
95% CI
Lower Upper
Forced Transfusion propensity .073 .434 .174 1.082
1 Functional status vs independent
Partially dependent .001 1.732 1.254 2.392
Fully dependent .019 1.966 1.120 3.451
2 On dialysis .001 3.003 2.067 4.363
3 Age .001 1.047 1.033 1.061
4 Emergency .001 2.061 1.405 3.025
5 ASA class vs 1 .001 Sig. across all values
ASA 2 .754 .692 .069 6.926
ASA 3 .585 .544 .061 4.846
ASA 4 .934 1.097 .123 9.772
ASA 5 .719 1.564 .137 17.841
6 Serum albumin .008 .736 .587 .922
7 BMI categ. Kg/m2 vs 18.5-25
18.5 .003 2.018 1.260 3.231
25.1-30.0 .184 .805 .585 1.108
30.1-35.0 .030 .586 .362 .949
35.1-40.0 .032 .376 .154 .922
40.0 .963 .979 .403 2.380
8 Hx cardiovasc. disease .003 1.740 1.200 2.523
9 BUN 40 .001 1.938 1.325 2.836
10 Bilirubin 1.0 .002 2.194 1.342 3.587
11 Systemic inflammation vs none
SIRS .009 1.747 1.152 2.650
Sepsis .376 .638 .236 1.725
Septic shock .137 1.923 .813 4.548
12 Male vs female .010 .691 .522 .915
13 Coma 24 hours postop .016 12.461 1.610 96.442
14 Pulmonary compromise .025 1.464 1.050 2.041
Forced Wound class vs clean
Clean/contaminated .362 1.424 .666 3.046
Contaminated .506 1.192 .711 1.997
Dirty/infected .081 1.630 .941 2.824
Forced Operative duration minutes .027 1.002 1.000 1.003
Forced Procedure type vs thromboendart.
Revasc. w/non-vein .296 .765 .463 1.265
Revasc. w/vein .020 .488 .267 .893
Forced Work RVUs .052 1.040 1.000 1.082
Forced Intraop transfusion vs none
1-2 u. .001 1.919 1.362 2.704
3 u. .001 2.482 1.548 3.978
Constant .001 .001ASA, American Society of Anesthesiologists; BMI, body mass index; RVUs, relative value units; SIRS, systemic inflammatory response syndrome.
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Step Variable Sig. Odds ratio
95% CI
Lower Upper
Forced Transfusion propensity .685 .921 .618 1.372
1 Functional status vs independent
Partially dependent .001 1.478 1.284 1.702
Fully dependent .001 2.202 1.585 3.057
2 Systemic inflammation vs none
SIRS .001 1.673 1.353 2.069
Sepsis .060 1.465 .984 2.180
Septic shock .121 1.740 .863 3.507
3 BMI categ. Kg/m2 vs 18.5-25.0
18.5 .752 .959 .739 1.245
25.1-30.0 .239 1.078 .951 1.222
30.1-35.0 .001 1.440 1.239 1.674
35.1-40.0 .001 1.697 1.373 2.096
40.0 .009 1.474 1.104 1.969
4 Rest pain .001 1.294 1.165 1.437
5 ASA class vs 1 .001 Sig. across all values
ASA 2 .146 .538 .233 1.241
ASA 3 .290 .646 .287 1.452
ASA 4 .723 .863 .382 1.951
ASA 5 .546 1.452 .432 4.877
6 Emergency .001 1.650 1.366 1.994
7 Male vs female .001 .755 .678 .840
8 Pulmonary compromise .001 1.265 1.098 1.457
9 Hx stroke/TIA .004 1.206 1.061 1.371
10 SGOT 40 .007 1.333 1.082 1.643
11 Creatinine 1.2 .002 1.189 1.063 1.330
12 PT 13.2 .002 1.187 1.065 1.324
13 Sodium 135 .006 1.230 1.061 1.426
14 CNS tumor .037 6.103 1.119 33.294
15 Hx cardiovascular disease .003 1.334 1.104 1.611
16 Recent 10% weight loss .031 1.461 1.035 2.062
17 Preop transfusion 5 u. .028 2.572 1.105 5.988
Forced Wound class vs clean .019
Clean/contaminated .074 1.300 .975 1.733
Contaminated .059 1.245 .992 1.562
Dirty/infected .103 .797 .607 1.047
Forced Operative duration minutes .001 1.002 1.001 1.003
orced Procedure type vs thrombo endarterectomy .401
Revasc. w/non-vein .180 1.152 .937 1.416
Revasc. w/vein .305 1.129 .895 1.425
orced Work RVUs .004 1.022 1.007 1.037
orced Intraop transfusion vs none
1-2 u. .001 1.369 1.188 1.577
3 u. .001 1.812 1.463 2.243
Constant .001 .090ASA, American Society of Anesthesiologists; BMI, body mass index; RVUs, relative value units; TIA, transient ischemic attack.
